skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain

Review

(2487) Views  (781) Full article downloads

Authors: Howard S Smith, Timothy R Deer

Published Date July 2009 Volume 2009:5 Pages 521 - 534
DOI: http://dx.doi.org/10.2147/TCRM.S4438

Howard S Smith,1 Timothy R Deer2

1Albany Medical College, Department of Anesthesiology, Albany, New York, USA; 2The Center for Pain Relief, Clinical Professor, West Virginia, University, Charleston, West Virginia, USA

Abstract: Ziconotide is a conopeptide intrathecal (IT) analgesic which is approved by the US Food and Drug Administration (FDA) for the management of severe chronic pain. It is a synthetic equivalent of a naturally occurring conopeptide found in the venom of the fish-eating marine cone snail and provides analgesia via binding to N-type voltage-sensitive calcium channels in the spinal cord. As ziconotide is a peptide, it is expected to be completely degraded by endopeptidases and exopeptidases (Phase I hydrolytic enzymes) widely located throughout the body, and not by other Phase I biotransformation processes (including the cytochrome P450 system) or by Phase II conjugation reactions. Thus, IT administration, low plasma ziconotide concentrations, and metabolism by ubiquitous peptidases make metabolic interactions of other drugs with ziconotide unlikely. Side effects of ziconotide which tend to occur more commonly at higher doses may include: nausea, vomiting, confusion, postural hypotension, abnormal gait, urinary retention, nystagmus/amblyopia, drowsiness/somnolence (reduced level of consciousness), dizziness or lightheadedness, weakness, visual problems (eg, double vision), elevation of serum creatine kinase, or vestibular side effects. Initially, when ziconotide was first administered to human subjects, titration schedules were overly aggressive and led to an abundance of adverse effects. Subsequently, clinicians have gained appreciation for ziconotide’s relatively narrow therapeutic window. With appropriate usage multiple studies have shown ziconotide to be a safe and effective intrathecal analgesic alone or in combination with other intrathecal analgesics.

Keywords: pain, ziconotide, intrathecal analgesics, safety, patient acceptability








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
A combined Phase I and II open-label study on the immunomodulatory effects of seaweed extract nutrient complex
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum